Medplus Health Services (MEDPLUS)₹596.00−2.67%Pharmacy Retail
In the Sep 2026 quarter (consolidated), Medplus Health Services reported sales of ₹2,043 Cr, up 21.4% from Sep 2025, and net profit of ₹55.75 Cr, down 0.1% year on year. For the year to Mar 2026, sales were ₹6,910 Cr and net profit ₹219 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,445 | 1,495 | 1,494 | 1,580 | 1,564 | 1,514 | 1,548 | 1,683 | 1,811 | 1,869 | 1,886 | 2,043 |
| Expenses | 1,354 | 1,391 | 1,400 | 1,458 | 1,434 | 1,378 | 1,417 | 1,535 | 1,653 | 1,702 | 1,754 | 1,874 |
| Operating Profit | 92.34 | 106 | 94.26 | 124 | 133 | 136 | 131 | 149 | 160 | 169 | 133 | 170 |
| OPM % | 6.0% | 7.0% | 6.0% | 8.0% | 8.0% | 9.0% | 8.0% | 9.0% | 9.0% | 9.0% | 7.0% | 8.0% |
| Other Income | 9.99 | 9.99 | 8.99 | 11.99 | 12.99 | 15.98 | 14.98 | 16.97 | 17.98 | 20.99 | 19.97 | 20.97 |
| Interest | 24.03 | 24.99 | 24.99 | 25.01 | 26.02 | 27.01 | 27.02 | 29.01 | 31.02 | 33.01 | 33.04 | 37.03 |
| Depreciation | 57.15 | 59.16 | 60.17 | 63.21 | 62.21 | 64.16 | 66.14 | 69.22 | 73.17 | 76.23 | 78.18 | 84.25 |
| Profit before tax | 19.93 | 31.90 | 17.95 | 47.84 | 56.81 | 60.84 | 52.84 | 68.75 | 72.77 | 79.78 | 41.84 | 69.82 |
| Tax % | 30.9% | −5.0% | 18.9% | 18.9% | 18.9% | 15.9% | 19.9% | 18.9% | 20.9% | 19.9% | 21.0% | 19.9% |
| Net Profit | 13.95 | 33.85 | 13.94 | 38.88 | 45.84 | 50.85 | 41.85 | 55.80 | 57.80 | 63.80 | 32.86 | 55.75 |
| EPS (Rs) | 1.16 | 2.80 | 1.21 | 3.25 | 3.84 | 4.30 | 3.55 | 4.64 | 4.83 | 5.35 | 2.77 | 4.68 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,738 | 2,016 | 2,137 | 2,278 | 2,880 | 3,076 | 3,788 | 4,573 | 5,643 | 6,153 | 6,910 | 7,609 |
| Expenses | 1,702 | 1,946 | 2,082 | 2,161 | 2,747 | 2,860 | 3,518 | 4,306 | 5,291 | 5,670 | 6,309 | 6,983 |
| Operating Profit | 37.12 | 71.20 | 58.20 | 120 | 134 | 218 | 274 | 267 | 356 | 489 | 610 | 633 |
| OPM % | 2.1% | 3.5% | 2.7% | 5.0% | 4.7% | 7.0% | 7.0% | 6.0% | 6.0% | 8.0% | 9.0% | 8.3% |
| Other Income | 7.99 | 6.99 | 7.99 | 10.98 | 16.98 | 20.98 | 30.96 | 45.92 | 39.96 | 47.95 | 70.97 | 79.91 |
| Interest | 17.01 | 19.01 | 28.02 | 49.99 | 47.03 | 55.04 | 66.08 | 83.01 | 95.99 | 103 | 120 | 134 |
| Depreciation | 10.03 | 11.03 | 12.03 | 59.14 | 75.25 | 88.22 | 119 | 182 | 225 | 251 | 284 | 312 |
| Profit before tax | 18.94 | 47.82 | 25.93 | 22.92 | 28.90 | 94.72 | 118 | 46.82 | 72.77 | 183 | 274 | 264 |
| Tax % | 51.9% | 39.9% | −65.1% | 47.9% | 93.9% | 33.9% | 20.0% | −6.0% | 11.0% | 17.9% | 19.9% | — |
| Exceptional items | 0.00 | −1.01 | 0.00 | 0.00 | 0.00 | 2.01 | 3.01 | 2.01 | 3.01 | 7.02 | 3.01 | — |
| Net Profit | 8.96 | 28.89 | 41.84 | 11.95 | 1.99 | 62.75 | 94.59 | 49.82 | 65.71 | 150 | 219 | 210 |
| EPS (Rs) | 45.32 | 144.46 | 169.80 | 47.76 | 8.74 | 278.13 | 8.05 | 4.18 | 5.50 | 12.59 | 18.35 | 17.63 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.18 | 0.18 | 0.18 | 0.20 | 0.20 | 0.20 | 0.46 | 24.08 | 24.09 | 24.08 | 24.06 | 24.07 |
| Reserves | 141 | 137 | 148 | 303 | 290 | 526 | 729 | 1,392 | 1,464 | 1,550 | 1,712 | 1,946 |
| Borrowings | 170 | 223 | 205 | 163 | 430 | 478 | 592 | 817 | 902 | 1,012 | 1,123 | 1,428 |
| Other Liabilities | 126 | 149 | 184 | 180 | 239 | 345 | 246 | 363 | 408 | 419 | 502 | 534 |
| Total Liabilities | 438 | 509 | 536 | 645 | 959 | 1,349 | 1,567 | 2,596 | 2,798 | 3,006 | 3,361 | 3,933 |
| Fixed Assets | 66.80 | 76.73 | 80.85 | 82.79 | 376 | 418 | 516 | 797 | 1,134 | 1,238 | 1,293 | 1,590 |
| CWIP | 3.01 | 3.01 | 2.01 | 1.01 | 1.01 | 5.01 | 6.02 | 20.07 | 25.09 | 11.04 | 16.05 | 32.09 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 369 | 430 | 454 | 561 | 581 | 926 | 1,046 | 1,779 | 1,637 | 1,757 | 2,051 | 2,311 |
| Inventories | 253 | 309 | 334 | 362 | 393 | 643 | 749 | 913 | 1,140 | 1,336 | 1,342 | 1,378 |
| Trade receivables | 4.01 | 3.01 | 2.01 | 10.01 | 9.01 | 6.01 | 5.01 | 6.01 | 9.01 | 18.02 | 13.02 | 27.04 |
| Cash & equivalents | 48.09 | 50.08 | 41.11 | 58.15 | 50.06 | 141 | 119 | 34.04 | 285 | 142 | 368 | 463 |
| Total Assets | 438 | 509 | 536 | 645 | 959 | 1,349 | 1,567 | 2,596 | 2,798 | 3,006 | 3,361 | 3,933 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −18.98 | −16.97 | 33.93 | 31.91 | 147 | −6.98 | 2.99 | 170 | 89.82 | 144 | 539 | 495 |
| Cash from investing activity | −15.98 | −31.93 | −14.99 | −17.98 | −18.97 | −27.95 | −34.93 | −702 | 428 | −82.91 | −317 | −128 |
| Cash from financing activity | 66.86 | 34.95 | −28.96 | −0.99 | −82.87 | 89.81 | −5.99 | 439 | −170 | −198 | −227 | −255 |
| Net cash flow | 32.09 | −15.05 | −10.02 | 14.03 | 45.17 | 56.21 | −37.13 | −93.21 | 351 | −137 | −5.01 | 112 |
| Capex | 17.02 | 18.03 | 15.02 | 0.00 | 22.04 | 30.05 | 54.10 | 118 | 169 | 84.09 | 59.09 | 123 |
| Free cash flow | −35.01 | −35.06 | 19.03 | 32.05 | 125 | −37.05 | −51.05 | 56.04 | −78.09 | 61.04 | 482 | 373 |
| CFO / OP % | −26.1% | −19.1% | 69.9% | 95.9% | 133.0% | 6.0% | 15.0% | 75.0% | 39.0% | 49.0% | 120.0% | 94.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Inventory days | 84 | 82 | 76 | 76 | 78 | 101 | 113 | 112 | 117 | 111 | 106 | 99 |
| Days payable | 33 | 28 | 24 | 26 | 30 | 36 | 21 | 29 | 26 | 20 | 23 | 21 |
| Cash conversion cycle | 51 | 53 | 51 | 51 | 48 | 65 | 91 | 82 | 91 | 92 | 83 | 79 |
| Working capital days | 16 | 12 | 14 | 13 | 8 | 25 | 46 | 100 | 58 | 58 | 54 | 49 |
| ROCE % | — | 11.0% | 19.0% | 13.0% | 12.0% | 9.0% | 13.0% | 10.0% | 5.0% | 7.0% | 10.0% | 13.0% |
For the Sep 2026 quarter, Medplus Health Services reported sales of ₹2,043 Cr, up 21.4% year on year and net profit of ₹55.75 Cr, down 0.1% year on year. The operating margin was 8.0%.
Medplus Health Services' sales for the year to Mar 2026 were ₹6,910 Cr; over the last twelve months they were ₹7,609 Cr.
Net profit for the year to Mar 2026 was ₹219 Cr, and ₹210 Cr over the last twelve months. Earnings per share over the same trailing period were ₹17.63.
Medplus Health Services reported borrowings of ₹1,428 Cr at Mar 2026, against cash and equivalents of ₹463 Cr.
Cash from operations was ₹495 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹373 Cr.